HDL-Atherosclerosis Treatment Study (HATS)
2 other identifiers
interventional
N/A
0 countries
N/A
Brief Summary
To measure the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Sep 1994
Typical duration for phase_3 cardiovascular-diseases
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 1994
CompletedFirst Submitted
Initial submission to the registry
October 27, 1999
CompletedFirst Posted
Study publicly available on registry
October 28, 1999
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2001
CompletedFebruary 10, 2016
March 1, 2005
October 27, 1999
February 8, 2016
Conditions
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Related Publications (7)
Brown G, Stewart BF, Zhao XQ, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol. 1995 Sep 28;76(9):93C-97C. doi: 10.1016/s0002-9149(99)80477-9.
PMID: 7572694BACKGROUNDBrown BG, Zhao XQ, Chait A, Frohlich J, Cheung M, Heise N, Dowdy A, DeAngelis D, Fisher LD, Albers J. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. Can J Cardiol. 1998 Apr;14 Suppl A:6A-13A.
PMID: 9594927BACKGROUNDCheung MC, Wolfbauer G, Brown BG, Albers JJ. Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease. Atherosclerosis. 1999 Jan;142(1):201-5. doi: 10.1016/s0021-9150(98)00190-7.
PMID: 9920522BACKGROUNDBrown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov 29;345(22):1583-92. doi: 10.1056/NEJMoa011090.
PMID: 11757504BACKGROUNDBrown BG, Cheung MC, Lee AC, Zhao XQ, Chait A. Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1535-46. doi: 10.1161/01.atv.0000034706.24149.95.
PMID: 12377728BACKGROUNDWilliams PT, Zhao XQ, Marcovina SM, Otvos JD, Brown BG, Krauss RM. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis. 2014 Apr;233(2):713-720. doi: 10.1016/j.atherosclerosis.2014.01.034. Epub 2014 Jan 30.
PMID: 24603218DERIVEDWilliams PT, Zhao XQ, Marcovina SM, Brown BG, Krauss RM. Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS One. 2013;8(2):e56782. doi: 10.1371/journal.pone.0056782. Epub 2013 Feb 27.
PMID: 23460815DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
Bruce Brown
University of Washington
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 27, 1999
First Posted
October 28, 1999
Study Start
September 1, 1994
Study Completion
February 1, 2001
Last Updated
February 10, 2016
Record last verified: 2005-03